Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386677 | 0.80 | CPT1B (0.54) | ALDH1A1LMNACES2KMT2ASRD5A2 | |
| SCHEMBL9811380 | 0.79 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2LMNACES2CES1 | |
| SCHEMBL3673930 | 0.79 | CES1 (0.48) | ALDH1A1SMN1; SMN2LMNACES2CES1 | |
| SCHEMBL3671533 | 0.78 | ALOX15 (0.54) | ALDH1A1LMNACES2CES1SRD5A2 | |
| P-Xylene SCHEMBL4557367 | 0.72 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2LMNACES2CES1 | |
| SCHEMBL1104323 | 0.72 | CES2 (0.75) | ALDH1A1SMN1; SMN2LMNACES2CES1 | |
| SCHEMBL10777265 | 0.72 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2LMNACES2CES1 | |
| Terephthalic Acid SCHEMBL526449 | 0.71 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2LMNACES2CES1 | |
| 4-Methylbenzoic Acid SCHEMBL93638 | 0.71 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2LMNACES2CES1 | |
| 4-Methylbenzoic Acid SCHEMBL1331178 | 0.71 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2LMNACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841457-B2 | Process for cyclooxygenase-2 selective inhibitor | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2014-09-23 | — | — | US | disclosed |
| EP-2649049-A2 | PRODUCE TO PRODUCE ETORICOXIB | Virdev Intermediates Pvt. Ltd. (IN) | 2013-10-16 | — | — | EP | disclosed |
| US-20130245272-A1 | PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2013-09-19 | — | — | US | disclosed |
| WO-2012066570-A2 | A PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2012-05-24 | — | — | WO | disclosed |
| US-4933367-A | Carboxylic acid derivatives, processes for the preparation thereof, the use thereof, and pharmaceutical compositions which contain these compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1990-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245272-A1 | PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | PTGS2, PTGIS, PTGES2 | ALDH1A1 404/4885SMN1; SMN2 3923/4885LMNA 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.